0A7L Stock Chart & Stats
$112.39
$2.69(2.39%)
At close: 4:00 PM EDT
$112.39
$2.69(2.39%)
Day’s Range― - ―
52-Week Range$97.71 - $206.00
Previous CloseN/A
Volume16.00
Average Volume (3M)33.00
Market Cap
$3.64B
Enterprise Value$4.05K
Total Cash (Recent Filing)$591.27M
Total Debt (Recent Filing)$727.35M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Oct 29, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding32,963,000
10 Day Avg. Volume66
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$174.78Price Target Upside55.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$886.87M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high-teens revenue growth indicates expanding utilization of iRhythm’s monitoring platform and stronger commercial execution. The raised annual outlook provides evidence that momentum is broad enough to support continued investment, scale benefits, and improved earnings power over the next several quarters.
Margin Expansion And Operating LeverageHigh gross margins and rapidly improving adjusted EBITDA show that revenue growth is translating into operating leverage rather than requiring proportionate cost increases. The cleared algorithm could further reduce technician review time, supporting durable efficiency gains and margin expansion.
VitalConnect Platform ExpansionVitalConnect would broaden iRhythm beyond its existing cardiac monitoring offering and add multi-parameter, inpatient, and several ambulatory modalities. With a key regulatory hurdle cleared, the transaction could expand the addressable market, deepen capabilities, and strengthen the combined platform.
Bears Say
Elevated LeverageThe debt-heavy capital structure reduces financial flexibility and leaves less capacity to absorb weaker operating results or fund strategic initiatives internally. Elevated leverage also increases the importance of sustained cash generation, because any deterioration in performance could constrain investment and capital allocation.
Profitability And Free Cash Flow Not Yet ConsistentDespite improving EBITDA and a strong recent quarter, iRhythm has not yet demonstrated consistently positive GAAP earnings or durable free-cash-flow conversion. Continued losses and modest trailing cash generation could limit balance-sheet repair and make future growth more dependent on execution and financing flexibility.
Outstanding FDA Warning LetterAn unresolved FDA warning letter creates ongoing regulatory uncertainty around the company’s operating environment and product roadmap. Although remediation and a third-party audit were submitted, delayed closure could require further resources, extend oversight, and complicate confidence in execution over the medium term.
Irhythm Technologies News
0A7L FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest share price was $97.71 and its highest was $206.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.64B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Oct 29, 2026 which is in 35 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is 0.02.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,963,000 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 3.61%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in GB:0A7L
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.78 (55.51% Upside)
$174.78 (55.51% Upside)
Blogger Sentiment
Bullish
GB:0A7L Sentiment 67%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
0A7L Company Deck
0A7L Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: high‑teens to low‑20% organic revenue growth, record profitability and free cash flow, raised guidance, constructive reimbursement news, and a strategic acquisition (VitalConnect) that expands modality, market opportunity and multivital capabilities. Notable risks discussed include an outstanding FDA warning letter, a recent cybersecurity incident, a $50 million litigation settlement, integration and regulatory review risks related to the VitalConnect acquisition, and the pending clearance of the company’s Zio MCT product. On balance, positive execution, margin expansion, and clear strategic rationale for the acquisition outweigh the manageable regulatory and integration headwinds.View all GB:0A7L earnings summaries0A7L Stock 12 Month Forecast
Average Price Target
$174.78
▲(55.51% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Koninklijke Philips
―
Medtronic
―
GE Healthcare Technologies Inc
―